Tvardi Therapeutics (NASDAQ:TVRD) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen lowered shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a strong sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. BTIG Research decreased their price objective on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. HC Wainwright assumed coverage on Tvardi Therapeutics in a research note on Monday, June 8th. They set a “buy” rating and a $9.00 target price on the stock. Finally, UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target for the company in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tvardi Therapeutics Stock Performance

Shares of TVRD opened at $1.27 on Friday. Tvardi Therapeutics has a 1 year low of $0.93 and a 1 year high of $43.65. The company has a market cap of $16.94 million, a price-to-earnings ratio of -0.46 and a beta of 0.32. The firm has a fifty day moving average of $1.92 and a 200-day moving average of $2.74.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Analysts predict that Tvardi Therapeutics will post -2.35 EPS for the current year.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TVRD. GSA Capital Partners LLP acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at $34,000. Susquehanna International Group LLP acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at $63,000. Finally, BlackRock Inc. bought a new position in Tvardi Therapeutics during the second quarter valued at about $181,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s approach is designed to address tumor growth, immune suppression and resistance to existing therapies by selectively targeting STAT3, a protein involved in cancer progression.

Tvardi’s lead product candidate is TTI-101, an orally administered small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors.